In Conversation with Rafiq Islam, Ph.D., Vice President, Bioanalysis and Biomarkers at Amador Bioscience and Maryland Site Head

Published on :

Amador Bioscience is a translational and early clinical development partner for companies developing new drugs. Make no mistake, though – Amador is different from many Contract Research Organizations (CROs) out there, using the latest scientific advancements as its north star to guide its decisions. The company leans on its technology-driven and AI-enabled capabilities to modernize clinical research and bioanalytical testing to accelerate new drugs through the development pipeline.

Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland

Published on :

Amador Bioscience, a global translational and clinical research CRO, is pleased to announce the grand opening of its GxP lab in Germantown, Maryland, on October 28, 2022. The 10,000+ square foot bioanalytical laboratory joins the company’s other facilities, which opened earlier this year in Belgium, China, and Ann Arbor, Michigan.